143 related articles for article (PubMed ID: 16123681)
1. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F; Carrat F; Pol S; Hor R; Rosenthal E; Goujard C; Morand P; Lunel-Fabiani F; Salmon-Ceron D; Piroth L; Pialoux G; Bentata M; Cacoub P; Perronne C;
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):47-52. PubMed ID: 16123681
[TBL] [Abstract][Full Text] [Related]
2. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
[TBL] [Abstract][Full Text] [Related]
3. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
Moreno A; Quereda C; Moreno L; Perez-Elías MJ; Muriel A; Casado JL; Antela A; Dronda F; Navas E; Bárcena R; Moreno S
Antivir Ther; 2004 Feb; 9(1):133-8. PubMed ID: 15040545
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
Laguno M; Milinkovic A; de Lazzari E; Murillas J; Martínez E; Blanco JL; Loncá M; Biglia A; Leon A; García M; Larrousse M; García F; Miró JM; Gatell JM; Mallolas J
Antivir Ther; 2005; 10(3):423-9. PubMed ID: 15918333
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
7. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
8. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
Butt AA
AIDS Read; 2003 Jul; 13(7):344-8. PubMed ID: 12889452
[TBL] [Abstract][Full Text] [Related]
9. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Bani-Sadr F; Goderel I; Penalba C; Billaud E; Doll J; Welker Y; Cacoub P; Pol S; Perronne C; Carrat F;
J Viral Hepat; 2007 Sep; 14(9):639-44. PubMed ID: 17697016
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.
Lo Re V; Kostman JR; Gross R; Reddy KR; Mounzer K; Zemel BS; Rennert H; Stieritz DD; Putt M; Frank I; Strom BL
J Acquir Immune Defic Syndr; 2007 Mar; 44(3):344-50. PubMed ID: 17179767
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
[TBL] [Abstract][Full Text] [Related]
14. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
[TBL] [Abstract][Full Text] [Related]
15. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
[TBL] [Abstract][Full Text] [Related]
16. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lafeuillade A; Hittinger G; Chadapaud S
Lancet; 2001 Jan; 357(9252):280-1. PubMed ID: 11214134
[TBL] [Abstract][Full Text] [Related]
17. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.
Reiberger T; Kosi L; Maresch J; Breitenecker F; Payer BA; Wrba F; Rieger A; Gangl A; Peck-Radosavljevic M
J Infect Dis; 2010 Jul; 202(1):156-60. PubMed ID: 20486858
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]